(Q41945708)

14 October 2017

title

Sustained remission of lupus nephritis (English)

1 reference

14 October 2017

C E H Barber

1

1 reference

14 October 2017

L Geldenhuys

series ordinal

2

1 reference

14 October 2017

J G Hanly

series ordinal

3

1 reference

14 October 2017

publication date

1 January 2006

1 reference

14 October 2017

1 reference

14 October 2017

volume

15

1 reference

14 October 2017

issue

2

1 reference

14 October 2017

page(s)

94-101

1 reference

Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

14 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Prognostic factors in lupus nephritis. Contribution of renal histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Treatment of severe proliferative lupus nephritis: the current state

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2271OA

10.1191/0961203306LU2271OA

21 January 2018

Identifiers

DOI

1 reference

14 October 2017

1 reference